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ARTICLE
PI3Kδ hyper-activation promotes development of
B cells that exacerbate Streptococcus pneumoniae
infection in an antibody-independent manner
Anne-Katrien Stark 1,2, Anita Chandra1,2,3,4, Krishnendu Chakraborty1,3, Rafeah Alam1, Valentina Carbonaro1,
Jonathan Clark5, Srividya Sriskantharajah6, Glyn Bradley7, Alex G. Richter8,9, Edward Banham-Hall1,3,4,
Menna R. Clatworthy10, Sergey Nejentsev3, J. Nicole Hamblin6, Edith M. Hessel6, Alison M. Condliffe11 &
Klaus Okkenhaug 1,2
Streptococcus pneumoniae is a major cause of pneumonia and a leading cause of death world-
wide. Antibody-mediated immune responses can confer protection against repeated expo-
sure to S. pneumoniae, yet vaccines offer only partial protection. Patients with Activated PI3Kδ
Syndrome (APDS) are highly susceptible to S. pneumoniae. We generated a conditional
knock-in mouse model of this disease and identify a CD19+B220− B cell subset that is
induced by PI3Kδ signaling, resides in the lungs, and is correlated with increased suscept-
ibility to S. pneumoniae during early phases of infection via an antibody-independent
mechanism. We show that an inhaled PI3Kδ inhibitor improves survival rates following S.
pneumoniae infection in wild-type mice and in mice with activated PI3Kδ. These results
suggest that a subset of B cells in the lung can promote the severity of S. pneumoniae
infection, representing a potential therapeutic target.
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S
treptococcus pneumoniae is an invasive extracellular bac-
terial pathogen and is a leading cause of morbidity and
mortality. Although S. pneumoniae can cause disease in
immunocompetent adults, it commonly colonizes the upper air-
ways without causing disease. The World Health Organization
has estimated that there are 14.5 million episodes of severe
pneumococcal disease and that 1.6 million people die of pneu-
mococcal disease every year1. Despite the implementation of
global vaccination programs, S. pneumoniae infection remains a
major disease burden1–3.
Invasive S. pneumoniae infection is a major cause of lower
airway infections (pneumonia), sepsis and meningitis. Healthy
people at the extremes of age are more susceptible to pneumo-
coccal disease, as are people with chronic obstructive pulmonary
disease (COPD), however those at greatest risk are patients with
splenic dysfunction or immune deﬁciency. This increased sus-
ceptibility results at least in part from the lack of protective
antibodies against conserved protein antigens or against poly-
saccharides that form part of the pneumococcal capsule4. Indeed,
the protective role of antibodies in pneumococcal disease is most
obvious in individuals with congenital (primary) immunodeﬁ-
ciencies (PIDs). This was ﬁrst recognized in a patient with X-
linked agammaglobulinemia (XLA), a syndrome subsequently
shown to be caused by a block in B cell development due to loss-
of-function mutations in BTK5–7. These patients remain highly
susceptible to S. pneumoniae into adulthood, but can be effec-
tively treated by the administration of immunoglobulins from
healthy donors.
We and others have recently described cohorts of immune
deﬁcient patients with activating mutations in PIK3CD, the gene
encoding the p110δ catalytic subunit of phosphoinositide 3-
kinase δ (PI3Kδ)8–10. PI3Kδ is a lipid kinase that catalyzes the
phosphorylation of the phosphatidylinositol-(4,5)-bisphosphate
lipid to produce phosphatidylinositol-(3,4,5)-trisphosphate
(PIP3). PI3Kδ is expressed in cells of the immune system and
regulates many aspects of immune cell signaling, particularly in
lymphocytes11,12. Activated phosphoinositide 3-kinase δ syn-
drome (APDS) is a combined immunodeﬁciency affecting T and
B cells. APDS patients suffer from recurrent sinopulmonary
infections, with S. pneumoniae being the most commonly isolated
pathogen13. Eighty-ﬁve percent of APDS patients have been
diagnosed with pneumonia14. APDS patients are also more likely
to develop structural lung damage (bronchiectasis) than patients
with other PIDs13. The mechanism underpinning the increased
susceptibility to pneumococcal infection in APDS is unclear11.
Although APDS patients often lack IgG2, the protection afforded
by immunoglobulin replacement therapy is not as robust as that
observed in patients with pure antibody deﬁciencies, suggesting
that antibody-independent PI3Kδ-driven mechanisms may be
involved13. The monogenic nature of APDS allows us to dissect
mechanisms of susceptibility to S. pneumoniae infection on cel-
lular and molecular levels, and to determine whether PI3Kδ
inhibitors may help reduce the susceptibility to S. pneumoniae. If
so, PI3Kδ inhibitors, that are in development for the treatment of
inﬂammatory and autoimmune diseases, might also have wider
applications to reduce the pathological consequences of S.
pneumoniae infection15. In this study, we have explored
mechanisms by which PI3Kδ hyperactivation drives susceptibility
to S. pneumoniae infection. We found that the administration of
the PI3Kδ-selective inhibitor nemiralisib (GSK-22696557)16,17
reduced the severity of pneumococcal disease in wild-type mice.
To investigate this further, we generated a p110δE1020K mouse
model that accurately recapitulates the genetics and immunolo-
gical phenotype of APDS, and displays increased susceptibility to
S. pneumoniae infection. We show that this susceptibility segre-
gates with enhanced PI3Kδ signaling in B cells, which exacerbate
S. pneumoniae infection at early time points before the adaptive
immune response comes into play. Of note, we have identiﬁed a
previously unappreciated population of CD19+B220− IL-10-
secreting cells that was present in wild-type mice but expanded
10–20-fold in p110δE1020K mice. We demonstrate that nemir-
alisib reduces the frequency of IL-10-producing B cells in the lung
and improves survival of p110δE1020K mice. Similarly, a higher
proportion of transitional B cells from APDS patients produced
IL-10 and this was reduced by nemiralisib. This study provides
new insights into the pathogenesis of the early stages of invasive
S. pneumoniae disease and offers the potential of future ther-
apeutic strategy to alleviate the severity of this disease in sus-
ceptible patients.
Results
Nemiralisib improves S. pneumoniae infection outcome in
mice. Given that APDS patients are more susceptible to S.
pneumoniae, we sought to determine whether nemiralisib, an
inhaled PI3Kδ inhibitor which is in development for the treat-
ment and prevention of COPD excacerbations16,17, would alter
susceptibility to airway infections. We treated mice with nemir-
alisib and then infected them intranasally with S. pneumoniae
(TIGR4, serotype 4). Nemiralisib-treated mice showed prolonged
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Fig. 1 Prophylactic, but not therapeutic treatment with the inhaled PI3Kδ inhibitor nemiralisib mitigates disease severity following S. pneumoniae infection in
wild-type mice. Wild-type mice were treated twice daily with the inhaled PI3Kδ inhibitor nemiralisib for the duration of the study: when treatment was
started 24 h prior to infection with S. pneumoniae serotype 4, TIGR 4, survival rates were improved. When started 8 or 24 h post-infection, the treatment
had no effect on survival outcome. (−24 h: data from ﬁve independent experiments combined n= 60; +8 h/+24 h: data from three independent
experiments combined n= 36; data-points represent individual animals)
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survival compared to mice given vehicle control (Fig. 1). This
protection was only effective if the drug was administered before
and during infection (Fig. 1). By contrast, nemiralisib adminis-
tration 8 or 24 h post-infection had no impact on survival of the
mice. These data suggest that PI3Kδ modulates the immune
response during early S. pneumoniae infection, either by inhi-
biting protective immunity, or by promoting an adverse response.
Hyperactive PI3Kδ signaling alters lymphocyte development.
We generated a conditional knock-in mouse harboring mutation
E1020K in the Pik3cd gene that is equivalent to the most common
APDS-causing mutation E1021K in humans (Supplementary
Fig. 1). These mice were subsequently crossed with different Cre-
expressing lines to either generate germline mice where
p110δE1020K is expressed in all cells (p110δE1020K-GL) or selectively
in B cells using Mb1Cre (p110δE1020K-B), in T cells using Cd4Cre
(p110δE1020K-T) or myeloid cells using Lyz2Cre (p110δE1020K-M).
We studied p110δE1020K mice in comparison with wild-type and
p110δD910A mice that have catalytically inactive p110δ18.
Initially, we tested if p110δE1020K mice have increased PI3Kδ
activity and display the characteristic immunological phenotype of
APDS. Biochemical analyzes of B cells and T cells from
p110δE1020K-GL mice conﬁrmed that the kinase is hyperactive
(Fig. 2). Measurements of PIP3 in T cells showed that p110δE1020K
is about six times as active as the wild-type kinase following
stimulation with anti-CD3 and anti-CD28, but with no evidence for
increased basal activity (Fig. 2a). In B cells, p110δE1020K led to
increased basal PIP3 levels, but it was further increased only about
two-fold compared to wild-type mice after stimulation with anti-
IgM (Fig. 2b). This pattern resembles results found in patients with
APDS9. In wild-type and p110δE1020K-GL cells, the PI3Kδ-selective
inhibitor nemiralisib reduced PIP3 to the background level observed
in p110δD910A cells, which, as expected, were insensitive to
nemiralisib (Fig. 2a, b).
PIP3 binds to the protein kinase AKT, supporting its
phosphorylation on Thr308 and subsequent activation. Western
blotting of puriﬁed p110δE1020K-GL T cells showed increased AKT
phosphorylation following stimulation with anti-CD3 and anti-
CD28 antibodies compared to wild-type cells, whereas AKT
phosphorylation in p110δD910A T cells was below the limit of
detection (Fig. 2c). In B cells, both basal and anti-IgM-induced
phosphorylation of AKT were elevated in p110δE1020K-GL cells,
while strongly diminished in p110δD910A B cells (Fig. 2d). The
phosphorylation of ERK and the AKT effector proteins, FOXO
and S6, were similarly affected. All phosphorylation events in
wild-type and p110δE1020K-GL cells were reduced to the levels
observed in p110δD910A cells by inhibition with nemiralisib. As
expected, p110δ protein expression was not affected by the
E1020K or D910A mutations (Fig. 2c, d).
Germline p110δE1020K-GL mice had near normal numbers of
myeloid cells in the bone marrow and spleen. In the bone marrow
we observed a signiﬁcant B cell lymphopenia that was associated
with a block in B cell development between Pro-B and Pre-B cells
and did not extend to the spleen. Although these mice
had normal numbers of splenic B cells, there was an increased
proportion of marginal zone B and B1 cells with an altered
distribution of transitional B cells (Fig. 3). The thymus of
p110δE1020K-GL mice was normal except for a mild reduction in
single positive CD8+ T cells. In the spleens and lymph nodes
there were increased proportions of activated/memory T cells
identiﬁed by high CD44 expression and low CD62L expression,
and increased numbers of Foxp3+ T regulatory cells
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Fig. 2 PI3Kδ hyper-activation leads to increased PIP3 and pAKT levels that can be reduced using a selective PI3Kδ inhibitor. a PIP3 levels in puriﬁed T cells
from wild-type, p110δE1020K and p110δD910A mice, unstimulated or stimulated with anti-CD3 and anti-CD28 in the presence or absence of the selective
PI3Kδ inhibitor, nemiralisib (mean ± SD; n= 2–3). b PIP3 levels in puriﬁed B cells from wild-type, p110δ
E1020K and p110δD910A mice unstimulated, or
stimulated with anti-IgM in the presence or absence of nemiralisib (mean ± SD n= 2–6). cWestern blots of puriﬁed T cells from wild-type, p110δE1020K and
p110δD910A mice, unstimulated or stimulated with anti-CD3 and anti-CD28 in the presence or absence of nemiralisib. d Western blots of puriﬁed B cells
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NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05674-8 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:3174 | DOI: 10.1038/s41467-018-05674-8 |www.nature.com/naturecommunications 3
(Supplementary Fig. 2). These T cell and B cell phenotypes were
recapitulated in p110δE1020K-T and p110δE1020K-B mice, respec-
tively (Supplementary Figs 3 and 4). The reciprocal effects of the
inhibitory D910A and activating E1020K mutations on speciﬁc
cell subsets demonstrate the pivotal role of PIP3 during
lymphocyte development and highlight the importance of a tight
control of PI3Kδ activity.
Analysis of serum immunoglobulins showed that p110δE1020K-GL
mice had elevated levels of IgG1 and IgG2b and a trend towards
increased levels of IgG2c, IgA, and IgE isotypes compared to wild-
type mice. There was also a trend to hyper IgM in p110δE1020K-GL
mice as is frequently observed in APDS patients9,10,13, whereas
p110δD910A mice were antibody deﬁcient (Supplementary Fig. 5).
The level of serum IgG3, which has been shown to be protective
G
a
te
d
 o
n
 B
2
2
0
+
C
D
1
9
+
G
a
te
d
 o
n
 B
2
2
0
+
C
D
9
3
+
Ig
M
CD23
Spleen
p110δWT p110δE1020K p110δD910A
L
iv
e
 c
e
lls
B220
C
D
1
9
0.3
105
105
104
104
103
103
–103
–103
0
0
57 4.0 35 0.01 47
C
D
2
1
CD23
5
81
10
0.06
94
4
9
57
26
40 28
156
20 53
126
52 11
1112
a
B220
C
D
1
9
Ig
M
C
D
2
5
Ig
D
B220
B220
CD19
25 1817
6
54
22
38
43 35
35
2 6
35 7 4
Bone marrow
L
iv
e
 c
e
lls
L
iv
e
 c
e
lls
L
iv
e
 c
e
lls
G
a
te
d
 o
n
B
2
2
0
+
Ig
M
–
p110δWT p110δE1020K p110δD910A
W
T
E
1
0
2
0
K
D
9
1
0
A
0.0
5.0×106
1.0×107
1.5×107
2.0×107
C
D
1
9
+
B
2
2
0
+
 c
e
lls
/B
M
W
T
E
1
0
2
0
K
D
9
1
0
A
0
1×106
2×106
3×106
4×106
Im
m
a
tu
re
 B
 c
e
lls
/B
M
W
T
E
1
0
2
0
K
D
9
1
0
A
0
2×106
4×106
6×106
M
a
tu
re
 B
 c
e
lls
/B
M
W
T
E
1
0
2
0
K
D
9
1
0
A
0
1×106
2×106
3×106
4×106
5×106
P
ro
B
 c
e
lls
/B
M
W
T
E
1
0
2
0
K
D
9
1
0
A
0
1×106
2×106
3×106
4×106
5×106
P
re
B
 B
 c
e
lls
/B
M
W
T
E
1
0
2
0
K
D
9
1
0
A
0
1×106
2×106
3×106
4×106
5×106
T
ra
n
s
it
io
n
a
l 
B
 c
e
lls
 /
B
M
Bone marrow
b Spleen
W
T
E
1
0
2
0
K
D
9
1
0
A
0
1×107
2×107
3×107
4×107
C
D
1
9
+
B
2
2
0
+
 c
e
lls
/S
p
le
e
n p < 0.0001
p < 0.0001
W
T
E
1
0
2
0
K
D
9
1
0
A
0
2×106
4×106
6×106
8×106
1×107
B
1
 c
e
lls
/s
p
le
e
n
p < 0.0001p < 0.0001
p < 0.0004
p < 0.0001
p < 0.0001
p < 0.0016
p < 0.00384 p < 0.0001
p = 0.0001
p = 0.0001
p < 0.0001
p < 0.0001 p < 0.0001
p < 0.0001p < 0.0001
p < 0.0001
p < 0.0001
p < 0.0001
p < 0.0007
p < 0.0001p < 0.0013
p < 0.0001
p < 0.0001
p < 0.0001
p < 0.0001 p < 0.0001
W
T
E
1
0
2
0
K
D
9
1
0
A
0
1×106
2×106
3×106
4×106
M
a
rg
in
a
l 
z
o
n
e
B
 c
e
lls
/s
p
le
e
n
W
T
E
1
0
2
0
K
D
9
1
0
A
0
5×106
1×107
1.5×107
2×107
2.5×107
F
o
lli
c
u
la
r 
B
 c
e
lls
/s
p
le
e
n
W
T
E
1
0
2
0
K
D
9
1
0
A
0
2×106
4×106
6×106
8×106
T
ra
n
s
it
io
n
a
l 
B
 c
e
lls
T
1
/S
p
le
e
n
W
T
E
1
0
2
0
K
D
9
1
0
A
0
1×106
2×106
3×106
T
ra
n
s
it
io
n
a
l 
B
 c
e
lls
T
2
/S
p
le
e
n
W
T
E
1
0
2
0
K
D
9
1
0
A
0
5×105
1×106
1.5×106
2×106
T
ra
n
s
it
io
n
a
l 
B
 c
e
lls
T
3
/S
p
le
e
n
105
104
103
–103
0
105
104
103
–103
0
105104103–103 0 105104103–103 0
105
104
103
–103
0
105
104
103
–103
0
105
104
103
–103
0
105
104
103
–103
0
105
104
103
–103
0
105
104
103
–103
0
105
104
103
–103
0
105
104
103
–103
0
105
104
103
–103
0
105
104
103
–103
0
105
104
103
–103
0
105
104
103
–103
0
105
104
103
–103
0
105
104
103
–103
0
105
104
103
–103
0
105
104
103
–103
0
105
104
103
–103
0
105
104
103
–103
0
105104103–103 0
105104103–103 0
105104103–103 0
105
105
104
104
103
103
–103 0
0 1051041030 1051041030
105104103–103 0 105104103–103 0
105104103–103 0 105104103–103 0
105104103–103 0 105104103–103 0
105104103–103 0 105104103–103 0
105104103–103 0 105104103–103 0 10
5104103–103 0
4 5
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05674-8
4 NATURE COMMUNICATIONS |  (2018) 9:3174 | DOI: 10.1038/s41467-018-05674-8 | www.nature.com/naturecommunications
against S. pneumoniae18, was comparable in p110δE1020K-GL and
wild-type mice (Supplementary Fig. 5).
PI3Kδ hyperactivation drive susceptibility to S. pneumoniae.
Given that the immunological phenotype of p110δE1020K-GL mice
strongly resembled that of APDS patients, we sought to determine
whether these mice recapitulate the increased susceptibility to S.
pneumoniae observed in APDS patients. We infected
p110δE1020K-GL, p110δD910A, and p110δWT mice with S. pneu-
moniae (TIGR4 serotype 4) and followed their survival for
10 days (Fig. 4a). Interestingly, p110δD910A mice did not show
increased susceptibility to S. pneumoniae. By contrast,
p110δE1020K-GL mice showed accelerated disease onset and
increased mortality (Fig. 4a). Natural antibodies against phos-
phorylcholine (PC) can offer protection against infection with
encapsulated bacteria, including S. pneumoniae19,20. We found
that p110δD910A mice lacked anti-PC antibodies, presumably
because of the absence of B1 and MZ B cells which are the major
source of natural antibodies18,21–23. By contrast, anti-PC anti-
bodies in the serum from p110δE1020K mice were similar (IgM) or
elevated (IgG) (Fig. 4b, c) compared to wild-type mice. Therefore,
susceptibility to S. pneumoniae in p110δE1020K mice cannot be
explained by a failure to produce natural antibodies against
conserved bacterial epitopes.
In order to determine the cell type responsible for increased
susceptibility to S. pneumoniae, we next infected the lineage-
restricted p110δE1020K-B, p110δE1020K-T and p110δE1020K-M mice.
Myeloid expression of p110δE1020K had no effect on the course of S.
pneumoniae infection (Fig. 4d), whereas expression of p110δE1020K
in T cells was protective (Fig. 4e). Only the p110δE1020K-B mice
replicated the increased susceptibility of the p110δE1020K-GL mice
to S. pneumoniae (Fig. 4f). Furthermore, transfer of p110δE1020K-B
bone marrow into irradiated RAG2−/− recipients also conferred
increased susceptibility to infection, which was only partially
rescued by co-transferring wild-type and p110δE1020K-B bone
marrow at a 1:1 ratio (Fig. 4g). These results indicate that B cells
drive the increased susceptibility to S. pneumoniae infection in
p110δE1020K-GL mice in an immune-dominant manner.
B cell mediated susceptibility is antibody-independent. In order
to further investigate antibody-mediated protection in the context
of PI3Kδ hyper-activation, we immunized mice with Pneumovax,
a 23-valent polysaccharide vaccine24. Following infection with S.
pneumoniae, wild-type mice were completely protected by this
vaccination protocol, while p110δE1020K-GL mice were only par-
tially protected, to a level similar to that in non-immunized wild-
type mice. By contrast, p110δD910A mice did not beneﬁt from
vaccination (Fig. 5a, b). Interestingly, p110δE1020K-GL mice and
wild-type mice produced a similar antibody response, in contrast
to p110δD910A mice that showed no response (Fig. 5c). These data
indicate that Pneumovax vaccination clearly protects against S.
pneumoniae, as shown in immunized wild-type mice. Despite this
protection p110δE1020K mice remained signiﬁcantly more sus-
ceptible to S. pneumoniae infection. Together, these data suggest
that B cells can affect susceptibility to S. pneumoniae by a
mechanism that is at least in part antibody-independent.
To determine more deﬁnitively whether B cells can be
pathogenic in the context of S. pneumoniae infection, we infected
wild-type and Ighmtm1 (µMT) mice which lack mature B cells25.
Strikingly, Ighmtm1 mice showed reduced susceptibility to S.
pneumoniae infection, delaying disease onset from ~2 days in
wild-type mice to ~5 days in Ighmtm1 mice (Fig. 6). Although
survival in Ighmtm1 mice was increased up to 30 days post
infection compared to wild-type mice, CFU counts from the lungs
of mice surviving to this time-point indicates that, despite
appearing clinically healthy, 41% (7/17) of Ighmtm1 mice failed to
clear the infection compared to 100% clearance in wild-type mice
(Fig. 6). Taken together, these results suggest that during early
time-points in the local infected environment B cells can be
pathogenic, while at later stages they are required to prevent
chronic infection.
Increased susceptibility to S. pneumoniae could either be due to
uncontrolled bacterial proliferation or be caused by an aberrant
immune response to the pathogen. The bacterial titers from lungs
and spleens of wild-type, p110δD910A and p110δE1020K-GL mice
were similar at 24 h post-infection, suggesting that the different
susceptibilities did not correlate with different abilities to control
bacterial outgrowth during the early phase of infection (Fig. 7a).
We observed a trend towards increased levels of TNFα, IL-6, IL-
1β, and IL-1α in the lung tissue of p110δE1020K-GL mice at 24 h
post-infection (Fig. 7b). Consistent with this, the levels of TNFα,
IL-6, and IL-1β were reduced in the lungs of wild-type mice
treated with nemiralisib prior to S. pneumoniae infection (Fig. 7c),
indicating that, while PI3Kδ signaling affect the amount of pro-
inﬂammatory cytokines produced in response to infection, the
increase in response to PI3Kδ hyper-activation is modest.
CD19+B220−B cells produce high levels of IL-10. We hypo-
thesized that increased susceptibility to S. pneumoniae infection
can be mediated by a speciﬁc subpopulation of B cells. Therefore,
we studied the B cell compartment in various tissues and found
an atypical population of CD19+B220−B cells that was rare in
wild-type mice, but signiﬁcantly increased in p110δE1020K-GL
mice and was absent in p110δD910A mice (Fig. 8a). In the spleen
and bone marrow, there was a 10-fold and 5-fold increase,
respectively, in the numbers of CD19+B220− B cells in
p110δE1020K-GL mice compared to wild-type mice (Fig. 8a).
Analysis of B cell conditional p110δE1020K-B mice show a similar
expansion of B220− B cells in the spleen (Fig. 8a), indicating that
the development of this population in response to PI3Kδ
hyperactivation is B-cell intrinsic. Infection with S. pneumoniae
did not induce further expansion of CD19+B220− B cells in the
lungs or other tissues examined 24 h post-infection (Fig. 8b).
To ascertain if these cells were also present in the lungs and to
distinguish resident from circulating cells, we labeled circulating
leukocytes in wild-type and p110δE1020K-GL mice by intravenous
injection of biotin-conjugated anti-CD45. We then stained the
lung homogenate with ﬂuorochrome-conjugated anti-mouse
Fig. 3 Phenotype of B cells in p110δE1020K-GL mice. a B cell subsets in the spleen and bone marrow from wild-type, p110δE1020K-GL and p110δD910A mice
were analyzed by ﬂow cytometry and representative pseudocolor plots with the mean cell proportion are shown. b In the spleen, the number of B1,
marginal zone (MZ) and T1 transitional cells B cells were increased in p110δE1020K-GL mice while follicular B cell numbers were normal. These populations
were reduced in p110δD910A mice. Analysis of the bone marrow showed normal pro-B cell numbers in p110δE1020K-GL mice with a reduced number of pre-B
cells, immature, transitional and mature B cells. Populations of cells are described as follows: Splenic B cells: Total B cells CD19+B220+, B1 cells CD19
+B220+CD23-CD21-, Follicular B cells CD19+B220+CD23+CD21+, Marginal zone B cells CD19+B220+CD23-CD21+, Transitional T1 B cells B220+CD93
+IgM+CD23-, Transitional T2 B cells B220+CD93+IgM+CD23+, Transitional T3 B cells B220+CD93+IgM−CD23−; Bone marrow B cells - Immature B
cells CD19+B220loIgM+, Mature B cells CD19+B220hiIgM+, Pro-B cells B220+IgM−CD19+CD25−, Pre-B cells B220+IgMCD19+CD25+, Transitional B
cells B220+IgD+. (Mean cell numbers are shown; combined data from two independent experiments, wild-type n= 10; p110δE1020K-GLn= 12; p110δD910An
= 7. Data-points represent individual animals)
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CD45 and streptavidin, and used ﬂow cytometry to distinguish
tissue resident leukocytes from those present in the lung
capillaries. We found a signiﬁcant increase in the proportion
and number of tissue-resident, but not circulating, B cells in
p110δE1020K-GL mice compared to wild-type mice. There was an
increase in both CD19+B220+ and CD19+B220– cells among the
tissue-resident B cells which demonstrates that both populations
can take residence in the lung (Supplementary Fig. 6).
Given that B cells from p110δE1020K-GL mice drive suscept-
ibility to S. pneumoniae in an antibody-independent manner, we
sought to look at other properties of B cells. We found lower IL-
10 protein levels and a signiﬁcant 10-fold decrease in IL-10
mRNA expression at 24 h post-infection in whole lung homo-
genates from wild-type mice treated with nemiralisib (Fig. 7c, d),
indicating that PI3Kδ signaling can regulate IL-10 levels in the
lung post infection. IL-10 is an important immune-regulatory
cytokine known to affect the course of S. pneumoniae
infection26,27 and therefore increased IL-10 production could
explain the B cell-dependent but antibody-independent effects
seen in p110δE1020K-GL mice. To investigate this further, we
crossed the p110δE1020K-GL and p110δD910A mice with a highly
sensitive IL-10 reporter (Il10ITIB) mouse28.
At 24 h post S. pneumoniae infection, the frequencies of the IL-
10-producing B cells were signiﬁcantly increased in the lungs of
p110δE1020K-GLIl10ITIB mice compared to wild-type Il10ITIB mice
(Fig. 7e). In addition, IL-10-producing B cells were barely
detected in lungs from p110δD910A mice (Fig. 7e). Frequencies of
the IL-10-producing CD11b+ myeloid, T and NK cells in lungs
were variable, but not consistently increased in p110δE1020K-GL
mice (Fig. 7e). Further analysis of the CD19+ B cell subset
isolated from lungs and spleens at 24 h post S. pneumoniae
infection showed that the proportion of IL-10-producing cells
was increased among the B220− B cell subset as compared to the
B220+ B cell subset in p110δE1020K-GL mice (5% B220+ vs. 68%
B220−) and wild-type mice (2% B220+ vs. 55% B220−) (Fig. 8c).
Furthermore, the proportion and absolute number of IL-10-
producing CD19+B220− cells and CD19+B220+ cells were
increased in p110δE1020K-GL mice compared to wild-type mice,
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Fig. 4 PI3Kδ hyper-activation leads to increased susceptibility to S. pneumoniae infection. a Germline p110δE1020K-GL mice show accelerated disease
development and signiﬁcantly increased mortality compared to control mice in response S. pneumoniae infection, while kinase dead p110δD910A mice do not
respond differently to wild-type mice. b–c Naïve PI3KδE1020K mice produce normal levels of anti-phosphorylcholine IgM and signiﬁcantly higher levels of
anti-PC IgG, while PI3KδD910A mice produce no natural antibody. d–f The p110δE1020K mutation was introduced conditionally into myeloid cells, T cells and
B cells by crossing onto Lyz2cre, Cd4cre and Mb1cre lines respectively. The myeloid conditional mutation did not affect survival following S. pneumoniae
infection in p110δE1020K-M mice (d), while T cell conditional p110δ hyper-activation led to improved survival in p110δE1020K-T mice (e). Introducing
the p110δE1020K mutation speciﬁcally in B cells (p110δE1020K-B mice) replicated the increased susceptibility to S. pneumoniae seen in p110δE1020K-GL
mice (f). g Transfer of p110δE1020K-B bone marrow into irradiated RAG2−/− recipients also conferred increased susceptibility to S. pneumoniae infection
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while such IL-10-producing cells were virtually absent in
p110δD910A mice (Fig. 8c). This indicates that CD19+B220−
cells are the predominant population of B cells that produce IL-10
in a PI3Kδ-dependent manner.
Previously, B cells that produce IL-10 have been termed B
regulatory cells (Bregs)29. We sought to compare the phenotype
of CD19+B220− IL-10-producing B cells with conventional IL-
10-producing CD19+B220+ Bregs described previously (Fig. 9).
Following in vitro stimulation for 5 h and analysis of cell surface
markers and intracellular IL-10 we found that there were clear
phenotypic differences between conventional B220+ Breg cells
and the B220− B cells we describe here, including the differential
expression of CD43 and IgM (Fig. 9). The lack of B220 expression
and low IgM expression differentiate the CD19+B220− IL-10-
producing B cells from conventional B1 cells30.
Nemiralisib reduces mortality in infected p110δE1020K mice.
Given that increased PI3Kδ activity in mice leads to increased
mortality after S. pneumoniae infection we explored if nemiralisib
would provide protection. Treatment of p110δE1020K-GL mice
with inhaled nemiralisib 24 h prior to infection led to a 20%
increase in survival. While nemiralisib treatment did not affect
the numbers of CD19+B220- B cells, the proportion of IL-10
producing CD19+B220- B cells in the lungs were reduced in
comparison to non-treated mice (Fig. 10a). This was in keeping
with our prior observations that nemiralisib treatment reduced
IL-10 mRNA levels in the lung tissue of S. pneumoniae infected
wild-type mice (Fig. 7d), suggesting a role for IL-10-producing
CD19+B220- B cells in the PI3Kδ-dependent susceptibility to
infection. Homozygous Il10ITIB mice are hypomorphic for IL-10
production. We exploited this property to assess if IL-10 deple-
tion would result in improved survival in p110δE1020K or WT
mice. Interestingly, systemic reduction of IL-10 in homozygous
Il10ITIB mice did not improve disease outcome (Supplementary
ﬁg. 7B). Furthermore, local depletion of IL-10 in the lung through
intranasal administration of anti-IL-10 did not improve disease
outcome in p110δE1020K mice (Supplementary ﬁg. 7D). These
data suggest that depletion of IL-10 is not sufﬁcient to revert they
p110δE1020K susceptibility phenotype. It is possible that there may
be a very speciﬁc role for IL-10 produced by the B220- B cells
related to the location of these cells in the lung that we could not
attenuate speciﬁcally using available tools and reagents. There
may also be other cytokines or secreted proteins that are co-
regulated with IL-10 in CD19+B220- B cells that are also
required. Indeed, Fig. 7d shows a number of cytokines that were
reduced by nemiralisib treatment of infected mice which have the
potential to affect the local response to infection. Further char-
acterization of this B cell subset may reveal such additional
mechanisms that can be tested experimentally.
Nemiralisib reduces IL-10 production in APDS patient B cells.
Cohort studies have shown that 75% of patients with APDS have
elevated circulating transitional B cells (CD19+IgM++CD38++)13.
Other studies have shown that such transitional B cells can produce
high levels of IL-1031,32. We obtained blood samples from patients
with APDS and healthy controls and conﬁrmed that all of these
APDS patients had elevated proportions of transitional B cells
(Fig. 10b). We isolated PBMCs from two of these APDS patients
and three healthy controls and stimulated them for 72 h with anti-
CD3 and IL-231. After stimulation we found more IL-10-producing
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B cells and more IL-10-producing transitional B cells in PBMCs of
APDS patients than in PBMCs of healthy controls, while treatment
with nemiralisib effectively suppressed IL-10 production in these
cells (Fig. 10c). Therefore, in keeping with reduction of CD19
+B220-IL-10 producing B cells in the mice, nemiralisib can also
reduce IL-10 producing human transitional B cells.
Discussion
Our results show that enhanced PI3Kδ signaling leads to the
increased susceptibility to S. pneumoniae infection through a B
cell-dependent, but antibody-independent mechanism. We found
an expansion of an aberrant B cell population which could be
equivalent to the elevated transitional B cell population found in
APDS patients. These cell populations may have a detrimental
effect during the early phase of S. pneumoniae infection.
In this study, we show that B cells can increase the suscept-
ibility to S. pneumoniae infection during the ﬁrst few hours after
exposure. Mice were more susceptible to S. pneumoniae infection
when the hyperactive p110δE1020K mutation was expressed in B
cells. By contrast, mice expressing the p110δE1020K mutation only
in T cells were protected. The basis for the protection remains
unknown and is the focus of ongoing study. The p110δE1020K
mice have increased numbers of TFH and Treg cells and the
conventional T cells have a more activated phenotype. A recent
study has documented a population of lung-resident innate Th17
cells that confers protection against re-challenge with S. pneu-
moniae33. Whether such a subset is affected by PI3Kδ activity and
can also protect against immediate challenge is not known.
However, we did not detect increased proportions of Th17 cells
after infection. Regardless of the mechanism, the protection
offered by T cells was overcome by the adverse effects of B cells in
p110δE1020K-GL mice.
We describe a subset of B cells which lack the common B cell
marker B220, and whose abundance is correlated with the sus-
ceptibility to S. pneumoniae infection. Moreover, we show that
the development of this CD19+B220- B cell subset is highly
dependent on the level of activity of PI3Kδ. Susceptibility to S.
pneumoniae infection was not altered in p110δD910A mice as
compared to wild-type mice. Kinase-dead p110δD910A mice lack
natural and anti-capsular antibodies which may make them more
susceptible, however, their lack of CD19+B220− B cells may
counterbalance this antibody deﬁciency, such that overall the
mutation has little net effect on S. pneumoniae susceptibility.
A large proportion of the CD19+B220− B cells produced IL-10.
Although increased IL-10 could potentially reduce the production
of inﬂammatory cytokines, we found similar or increased levels of
TNFα, IL-6 and IL-1 in the lungs of p110δE1020K mice and no
difference in CFU counts at 24 h post-infection.
One of the deﬁning characteristics of APDS patients is an
increased proportion of CD24+CD38+ B cells deﬁned as transi-
tional B cells9–11,13,14. Intriguingly, production of IL-10 is a char-
acteristic of these B cells as well. High IL-10 levels in response to
secondary S. pneumoniae infection following inﬂuenza A is asso-
ciated with increased lethality when compared to a primary S.
pneumoniae infection, and importantly, the outcome of a secondary
S. pneumoniae infection is improved by IL-10 neutralization26,27.
This indicates that, while IL-10 is required for normal immune
regulation and resolution of inﬂammation34, excess IL-10 during
the early stages of S. pneumoniae infection could have an acute
detrimental effect. This ﬁts with our observation that nemiralisib
treatment improved the outcome of mice infected with S. pneu-
moniae and reduced IL-10 mRNA levels in the lung. However, we
did not observe improved disease outcome in response to systemic
or local IL-10 depletion, indicating that increased IL-10 production
is not the sole mechanism driving increased pathology during S.
pneumoniae infection. Further studies are required to investigate
the time and location speciﬁc effects of B cell dependent IL-10
production, keeping in mind that B cells have the potential to
produce a number of different cytokines (such as IL-6, TNF-α, and
IL-35) which were affected by leniolisib treatment and which could
affect S. pneumoniae susceptibility35.
We postulate that the transitional B cells which are expanded
in APDS patients may not just be precursors to more mature B
cells, but also include cells that are functionally equivalent to the
CD19+B220− cells that we have identiﬁed in p110δE1020K mice
and thus may also contribute to the increased susceptibility to S.
pneumoniae infection and hence to the high incidence of
bronchiectasis characteristic of this disease14. In this context, it is
interesting that CD19+B220− B cells had previously been
described as immature progenitors in the bone marrow36, rather
than a functional PI3Kδ dependent subset found in peripheral
tissues as we describe here. Although the CD19+B220- B cells we
describe resemble B1 cells by some criteria, such as the expression
of CD5 and CD43, their lower IgM expression, lack of B220 and
distribution pattern suggest that they are related but distinct to
conventional B1 and B10 cells29,30. A similar subset has pre-
viously been described as being dependent on CD19 and
increased in the absence of PTEN expression and PTEN hap-
loinsufﬁency in humans can lead to an APDS-like syndrome37–39.
Our results do not question the important role that antibodies
play in the protection against S. pneumoniae and other encap-
sulated bacteria. Indeed, in wild-type mice, immunization with
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Pneumovax offered complete protection. Rather, our results
highlight a hitherto underappreciated subset of B cells that
increase the pathological response shortly after infection. It
remains to be determined whether this is a feature of the B cells
being lung-resident (and hence among the ﬁrst cells of the
immune system to encounter the invading pathogens) and by
which mechanisms B cells either condition lung epithelia to
become more susceptible to invasion of S. pneumoniae, reduce
the clearance of S. pneumoniae by phagocytes and/or increase the
collateral adverse effects of the early innate immune response to
this pathogen. This is in keeping with the increasing realization
that B cells are important sources of different cytokines and can
modulate immune responses independently of their capacity to
present antigen and produce antibodies35.
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Intriguingly, the inhaled inhibitor nemiralisib offered protection
in not just in p110δE1020K but also in wild-type mice infected with
S. pneumoniae, when administered prior to infection. This result
suggests that preventive inhibition of PI3Kδ can be beneﬁcial not
only just in the context of APDS, but also in other conditions
associated with PI3Kδ hyperactivation, such as COPD40.
The results presented herein are relevant to our understanding
and the potential treatment of patients with APDS. Clinical trials
are currently ongoing using both inhaled and systemic PI3Kδ
inhibitors (NCT02593539, NCT02435173, and NCT02859727).
Systemic use of a PI3Kδ inhibitor has shown promise in reduction
of lymphoproliferation and immune cell aberrations in patients
with APDS, however, no comments were made regarding recurrent
infections or respiratory manifestations41. Systemic use of PI3Kδ
inhibitors in malignancies have been associated with serious side
effects, including colitis42. It would therefore be of importance to
determine whether inhaled PI3Kδ inhibitors could alleviate the
respiratory manifestations of APDS while reducing the risk of the
adverse effects associated with systemic inhibition. Moreover, the
results may also be relevant to other conditions, such as COPD16,
where PI3Kδ may be activated by non-genetic mechanisms.
Overall, our ﬁndings suggest that in subjects with increased PI3Kδ
activity prophylactic administration of PI3Kδ inhibitors may help
alleviate the course of S. pneumoniae infection.
Methods
Ethics. Animal experiments were performed according to the Animals (Scientiﬁc
Procedures) Act 1986, licence PPL 70/7661 and approved by the Babraham
Institute Animal Welfare and Ethics Review Body.
Informed consent was obtained from patients and healthy controls. This study
conformed to the Declaration of Helsinki and according local ethical review
document 12/WA/0148.
Mouse strains and gene targeting. The p110δE1020K mice were generated by
Ozgene, Australia using homologous recombination in ES cells. A duplicate
sequence corresponding to the last coding exon in Pik3cd and carrying the E1020K
mutation was ﬂanked by loxP sites and inserted 3’ to the wild-type sequence. Upon
Cre-mediated recombination, the wild-type sequence is replaced by the mutant
E1020K sequence. p110δD910A, Cd4cre, Mb1cre, Lyz2cre, Ighmtm1 (µMT) and
Il10ITIB mice have been described previously18,25,28,43–45. Throughout the study,
the p110δE1020K allele was heterozygous whereas the p110δD910A alleles were
homozygous. Genotyping was performed by Transnetyx (Cordova, TN).
Throughout this study we used male and female animals aged between 8–15 weeks
in each experiment, wild-type controls were age and sex matched to genetically
modiﬁed mice.
S. pneumoniae stock preparation. Streptococcus pneumoniae (TIGR4, serotype 4
(provided by Professor Jeremy Brown, University College, London)) was grown to
mid-log phase (OD500= 0.5–0.7) in Todd-Hewitt broth (Oxoid) supplemented
with 0.5% yeast extract (Oxoid) at 37 °C, 5% CO2. The bacteria were collected by
centrifugation, and resuspended in PBS/20% glycerol (Sigma-Aldrich) prior to
freezing in liquid N2 and storage at −80 °C. Stocks were assessed for viable CFU
counts and homogeneity by plating out serial dilutions of three frozen samples on
blood agar plates (LB agar, supplemented with 5% deﬁbrinated sheep blood
(Oxoid)) after incubation for 24 h at 37 °C, 5% CO2. S. pneumoniae colonies were
conﬁrmed by the presence of an α-hemolytic zone and sensitivity to optochin
(Sigma-Aldrich). Virulent stocks were maintained by performing an in vivo pas-
sage every 6–12 months.
S. pneumoniae infections. Frozen stocks were thawed and washed twice by cen-
trifugation in sterile PBS before resuspending at 4 × 107 CFU/mL in PBS. The
suspension was kept on ice at all times, and used for infection within 2 h of thawing
(no loss of viability was observed under these conditions). Mice were lightly
anaesthetized by inhalation of 3% isoﬂurane and maintained with 2% isoﬂurane.
Mice (males and females aged 8–12 weeks) were infected intranasally with 50 µL S.
pneumoniae suspension containing 2 × 106 CFU. Animals were observed to con-
ﬁrm inhalation of the dose and full recovery from anesthesia. The infection dose
was routinely conﬁrmed by plating out serial dilutions of the inoculum on blood
agar plates, as described above.
Survival studies. Mice were infected with S. pneumoniae as described above. Pre-
infection body weights were recorded and animals were weighed daily post
infection. Animals were monitored three times a day for a period of 10 days post-
infection. Disease progression was assessed by assigning clinical scores without
knowledge of the individual genotypes: 0: Healthy; 1: mild clinical signs; 2: Up to 2
moderate clinical signs; 3: up to 3 moderate signs. Animals were culled when they
showed >25% bodyweight loss or reach score 3. The most frequently observed
clinical signs were piloerection, hunched posture, tremor, and labored breathing.
At the study end-point, animals were culled and terminal blood samples
collected.
Bone marrow transfer. A single cell suspension of p110δE1020K-B and wild-type
(C57Bl/6.SJL) donor bone marrow was prepared in sterile HBSS (Sigma-Aldrich) as
described below (Isolation of immune cells from mouse tissues). Cells from two
sex-matched donors were pooled. RAG2−/− recipient mice were supplied with 4
mg/mL Neomycin (Sigma-Aldrich) in drinking water before sub-lethal irradiation
(one dose of 500Rads over 63 s), and received 3 × 106 donor cells by intravenous
(tail vein) injection. Neomycin treatment was maintained for 4 weeks post-transfer,
and after 8 weeks reconstitution was conﬁrmed by analyzing tail bleeds.
Vaccination. For vaccine studies, mice were immunized with Pneumovax II
(pneumococcal polysaccharide vaccine, serotypes: 1–5, 6B, 7F, 8, 9N, 9V, 10A, 11A,
12F, 14, 15B. 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F; Sanoﬁ Pasteur MSD). One
0.5 mL dose containing 50 µg/mL of each serotype was diluted 1:12.5 in sterile PBS
to 4 µg/mL. Mice were given one 100 µL (0.4 µg) dose by intraperitoneal injection,
14 days before infection with S. pneumoniae. Blood samples were taken from the
tail vein prior to vaccination and 14 days after vaccination into serum collection
tubes (BD microtainer, SST) samples were centrifuged at 15000xg for 5 min and the
serum stored at −20 °C until analysis.
Nemiralisib and anti-IL-10 treatment. The PI3Kδ inhibitor nemiralisib
(GSK2269557) was supplied by GSK, Respiratory Refractory Inﬂammation DPU,
UK. The nemiralisib suspension was prepared on the day of use in 0.2% Tween80,
and administered intranasally to mice twice daily at 0.2 mg/kg in a total volume of
50 µL, as described above (S. pneumoniae infections). Unless otherwise speciﬁed,
the ﬁrst dose was given 24 h before infection, and treatment was maintained for the
duration of the study. Anti-IL-10 (JES5-2A5) and anti-HRPN rat IgG1 was pur-
chased from BioXcell and administered intranasally once daily as described above
at 200 µg/50 µL. Treatment was started 24 h before infection and maintained for
the duration of the study
Isolation of immune cells from mouse tissues. Mice were euthanized by CO2
inhalation and cervical dislocation. Lungs were perfused with 10 mL cold PBS
through the right ventricle, and collected into cold PBS. Lungs were homogenized
using a GentleMACS tissue dissociator and mouse lung dissociation enzyme kit
from Miltenyi according to the manufacter’s instructions. The homogenate was
transferred to 15 mL tubes (BD Falcon) and washed by centrifugation (500xg) in
10 mL cold PBS. The pellet was resuspended in 3 mL 37.5% isotonic Percoll
(Sigma) at room temperature and centrifuged at 650xg for 20 min with low
acceleration and no brake. The supernatant including tissue debris was removed,
and the cell pellet was washed and resuspended in cold PBS. Where CFU counts
were required, the right lung was processed as described above and the left lung
was processed for CFU counts as described below. Bone marrow cells were
Fig. 8 p110δE1020K mice have an expanded population of IL-10 producing CD19+B220− B cells. a Naïve p110δE1020K mice show a signiﬁcant increase in the
proportion and number of B220−B cells in bone marrow and spleen. While this population is detectable in wild-type mice, it is absent from p110δD910A
mice. Representative pseudocolor plots show mean cell proportions in naïve mice b S. pneumoniae (S.p) infection does not lead to signiﬁcant expansion or
recruitment of B220− B cells at 24 h post-infection in bone marrow, blood, spleen or lung tissue. Representative pseudocolor plots show mean cell
proportions in naïve mice. c At 24 h post S. pneumoniae infection, IL-10 production is increased in p110δE1020K B cells from both lung and spleen, and
reduced in p110δD910A B cells compared to wild-type mice. Furthermore, B220−B cells produce higher levels of IL-10 in response to S. pneumoniae infection
compared to B220+ B cells in wild-type and p110δE1020K mice. Representative pseudocolor plots show mean cell proportions in S. pneumoniae infected mice
(Mean cell counts are shown, data-points represent individual animals. a Combined data from two independent experiments, WT n= 10; E1020K n= 12;
D910A n= 7, b representative data from two independent experiments, n= 6, c representative data from two independent experiments n= 6)
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collected by ﬂushing cold PBS through femurs and tibias collected, ﬁltered through
40 µm cell strainers and washed by centrifugation in 5 mL PBS. Spleens, thymus
and peripheral lymph nodes were homogenized in PBS by pushing the tissue
through 40 µm cell strainers (BD) using a syringe plunge. The cell suspension was
then transferred to a 15 mL Tube (BD falcon) and washed once in 5 mL cold PBS.
For blood, bone marrow and spleen, red blood cells (RBC) were lysed using
hypotonic ammonium chloride RBC lysis buffer (Sigma). Lysing was quenched
with cold PBS and the cells were collected by centrifugation. Single cell suspensions
were processed for ﬂow cytometry as described below.
S. pneumoniae CFU counts. Lungs were homogenized in 1 ml PBS using a Bullet
Blender using 3 × 3 mm steel beads: speed 8, 3 min (Next Advance, USA). Spleens
were homogenized as described above in 2 mL PBS. Serial dilutions (10-fold) were
performed for spleen and lung homogenates, and samples were plated out on blood
agar as described above. Plates were incubated for 24 h at 37 °C and S. pneumoniae
colonies were counted.
In vitro stimulation of mouse B cells. Splenocytes were isolated from naïve wild-
type, p110δE1020K-GL and p110δD910A mice that had been crossed with the Il10ITIB
reporter line as described above and the total cell count was obtained using a CASY
counter. The cells were resuspended in complete RPMI (RPMI plus 5% (v/v) FCS,
50 μM β-mercaptoethanol and 100 μg/ml penicillin and streptomycin) and plated
at 5 × 106 cells in 100 µL per well in a 96-well U bottom plate. The cells were
stimulated with 10 ng/mL LPS, 50 ng/mL PdBu (Sigma, USA), 0.25 μg/mL Iono-
mycin (Sigma, USA) and 1 μL/mL of Brefeldin A (eBioscience) for 5 h at 37 °C. The
cells were then processed for IL-10 detection and ﬂow cytometry as described
below.
Detection of IL-10 in Il10ITIB reporter mice. Single cell suspensions from S.
pneumoniae infected mice or in vitro stimulated cells were prepared as described
above. The cells were incubated with 3.3 µM CCF4-AM, a Fluorescence Resonance
Energy Transfer substrate for β-lactamase (LiveBLAzer kit, Invitrogen), and 3.6
mM probenecid (Sigma) in complete RPMI for 90 min at 29 °C, as previously
described28, then placed on ice and collected by centrifugation. Cells were then
processed for ﬂow cytometry as described below.
Flow cytometry. Antibodies used for ﬂow cytometry are listed in Table 1. Single
cell suspensions were stained using an antibody master mix in PBS/0.5%BSA for
40 min at 4 °C. Cells were washed and ﬁxed in 4% paraformaldehyde (Biolegend)
for 10 min at room temperature before washing 2x in PBS/0.5%BSA. For intra-
cellular detection of IL-10 in human samples, the cells were ﬁxed and permeabi-
lized with Cytoﬁx/Cytoperm buffer (BD Biocsiences, USA) following surface
staining. For FoxP3 staining, the eBioscence FoxP3/Transcription Factor staining
Buffer Set was used according to the manufacturer’s instructions. Non-ﬂuorescent
counting beads (AccuCount Blank Particles 5.3 µm; Spherotech, USA) were added
to quantify absolute cells numbers. Samples were kept at 4 °C until analysis (BD
Fortessa5). Analysis was carried out using FlowJo (Treestar) analysis software.
In vitro stimulation of human B cells. Freshly isolated PBMCs from patients and
control individuals were stimulated with 0.5 μg/mL puriﬁed plate bound anti CD3
monoclonal antibody (clone-OKT3) (Invitrogen) and 20 ng/mL recombinant
human IL2 in presence or absence of, the p110δ inhibitor, nemiralisib (10 nM) for
72 h. This stimulation led to the activation of CD40L (CD154) on CD4 T cells. The
interaction between CD40L on CD4 T cells with CD40 on B cells resulted in the
production of IL-10 in regulatory B cells. For a ﬁnal stimulation 50 ng/mL PdBu
(sigma, USA), 0.25 μg/mL ionomycin (Sigma, USA) and 1 μL/mL of Brefeldin A
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(eBioscience) were also added for the last 4 h. Cells were washed, surface stained,
ﬁxed and permeabilized with Cytoﬁx/Cytoperm buffer (BD Biocsiences, USA) for
the intracellular detection of IL-10 as described above.
Natural antibody ELISA. Anti-phosphorylcholine IgM and IgG levels were
assessed in serum from naïve mice. Blood samples were collected by cardiac
puncture and serum collected as described above. NUNC Maxisorp ELISA plates
were coated overnight at 4 °C with 20 µg/mL phosphorylcholine-BSA (BioSearch)
in sodium bicarbonate coating buffer (pH9) (Biolegend) (100 µL/well). Plates were
washed 4× with PBS/0.2% Tween20 followed by blocking for 1 h at room tem-
perature in PBS/1%BSA. Serum samples were diluted 1:10 in PBS/1% BSA and
pooled WT serum was diluted from 1:5 to 1:400 to conﬁrm the linear range of the
assay. After removing the blocking solution, samples were added at 100 µL/well,
and the plates were incubated overnight at 4 °C. The plates were then washed 4x in
PBS/0.2%Tween20. Polyclonal HRP conjugated goat-anti-mouse IgM (abcam
ab97023) or IgG (abcam ab97230) was diluted 1:5000 in PBS/1% BSA, added at
100 µL per well and the plates were incubated for 2 h at room temperature. The
plates were washed 6× with PBS/0.2%Tween20, TMB substrate (Biolegend) was
added at 100 µL per well and incubated for 5–10 min at room temperature. The
reaction was stopped by adding 50 µL 2 N H2SO4 solution. Absorbance was read at
450 nm (Fluostar omega, BMG Labtech).
Tissue resident cell analysis (lung). Mice received an intravenous (tail vein)
injection of 3 µg anti-mouse CD45 conjugated to biotin (Biolegend, clone 30-F11)
in 100 µL PBS. Four minutes after injection animals were killed and the lungs were
collected into cold PBS without prior perfusion. Lungs were then ﬁnely minced
using a scalpel blade and the pushed through a 100 µm cell strainer (BD) the
homogenate was collected in a 15 mL tube (BD falcon) and washed in 10 mL cold
PBS. The pellet was resuspended in 3 mL 37.5% isotonic Percoll (Sigma) at room
temperature and processed as described above. The cells were stained for ﬂow
cytometry as described above, including streptavidin APC to identify anti-CD45-
Biotin labeled circulating cells.
Cytokine analysis. Cytokine levels were measured in the supernatant from lung
homogenates prepared for CFU analysis. The homogenates were centrifuged for 1
min at 10,000×g to remove tissue debris. Samples collected from wild-type mice
treated with nemiralisib were analyzed using Meso Scale Discovery mouse Th1/Th2
9-plex ultrasensitive kits, according to manufacturer’s instructions. Samples col-
lected from genetically modiﬁed mice were analyzed using the ﬂow cytometry
based Legendplex mouse inﬂammation 13-plex panel (Biolegend).
Gene arrays. Wild-type mice were treated with nemiralisib and infected with S.
pneumoniae as described above. At 24 h post-infection, whole lungs were collected
and snap frozen in liquid nitrogen. Samples were randomized and analyzed
(Affymetrix Genechip Mouse genome 430 2.0 Array) by Expression Analysis,
Quintiles Global Laboratories. Data analysis was performed by Computational
Biology and Statistics, Target Sciences, GlaxoSmithKline, Stevenage. Data was
normalized using the robust multiarray average method46 and quality checked in
R/Bioconductor47 using the affy package48. A linear model was ﬁtted to the RMA
normalized data for each probset and differential expression analysis was con-
ducted in the ArrayStudio software (Omicsoft Corporation). p-values were false
discovery rate corrected by the method of Benjamini and Hochberg49. Probes with
an absolute fold change >1.5 and an adjusted p-value < 0.05 were called signiﬁcant.
Luminex antibody analysis. Measurement of IgG recognizing pneumococcal
polysaccharide of 13 serotypes was performed as described previously50. The assay
was modiﬁed in order to measure murine IgG as follows: 50 µL of 1:10 diluted
mouse sera was added to each well containing the pneumococcal polysaccharides
coupled to microspheres and the secondary antibody used was 50 µL of 10 µg/mL
goat F(ab’)2 anti-mouse IgG (H+ L)- R-phycoerythrin (Leinco Technologies, Inc).
R-PE ﬂuorescence levels were recorded for each serotype and median ﬂuorescence
intensities were compared for the different genotypes.
PIP3 quantiﬁcation. CD4 and CD8 cells were isolated from mouse splenocytes
using immunomagnetic negative selection by biotinylated cocktail of antibodies
and Streptavidin dynabeads (Invitrogen). T cells were stimulated with anti-CD3 (1
mg/mL), (145-2c11, Biolegend) anti-CD28 (2 µg/mL), (35.51, Biolegend) anti-
bodies followed by crosslinking with anti-Armenian hamster IgG (10 µg/mL,
Jackson ImmunoResearch labs). Cells were stimulated for 1 min at 37 °C. B cells
were similarly isolated from mouse splenocytes and stimulated for 1 min at 37 °C
with anti-IgM 2 µg/mL (AfﬁnPure F(ab’)2 Fragment goat anti-mouse IgM from
Jackson Immuno-Research labs).
After stimulation of the cells, we terminated the reactions by addition of 750 µL
kill solution (CHCl3:MeOH:1 M HCL (10:20:1) and immediately froze the samples
on dry ice. PIP3 levels were quantiﬁed by mass spectrometry as previously
described51.
Western blotting. Puriﬁed T and B cells were isolated from murine spleens and
stimulated as described above (PIP3 measurement). For performing western blots
the stimulation period was 5 min. Isolated T cells were stimulated with anti-CD3 1
µg/mL and anti-CD28 (2 µg/mL) with or without 10 Nm nemiralisb; or B cells with
anti-IgM 4 µg/mL (AfﬁnPure F(ab’)2 Fragment goat anti-mouse IgM from Jackson
ImmunosResearch labs).
Stimulated T and B cells were lysed with ice-cold lysis buffer (50 mM HEPES,
150 mM NaCl, 10 mM NaF, 10 mM Indoacetamide, 1% IGEPAL and proteinase
inhibitors (Complete Ultra tablets, Roche)) for 15–20 min. Lysates were centrifuged
at 15,000×g for 10 min at 4 °C and supernatants were mixed with NuPage LDS
sample buffer (life technologies). Samples were heated at 70 °C and resolved on
4–12% NuPage bis-tris gel (Invitrogen), transferred to PVDF membranes and
probed with the following antibodies: pAKT (T308, Cell Signaling, 1 in 1000
dilution); total AKT1 (2H10, Cell signaling, 1 in 2000 dilution); p110δ (Sc7176,
Santa Cruz Biotechnology, 1 in 200 dilution); pS6 (S235/236, Cell Signaling, 1 in
500 dilution); pFoxo1/3a (T24/T32, Cell Signaling, 1 in 1000 dilution); pErk (p44/
42, Cell Signaling, 1 in 200 dilution); βActin (Sc47778, Santa Cruz Biotechnology, 1
in 2000 dilution).
Statistics and general methods
Sample selection. For animal studies where disease phenotype is
the outcome we determined that a minimum of 10–12 mice per
group is required to detect a 15% increase in survival with 80%
power with a two-sided signiﬁcance of 0.05. This result is based
Table 1 Antibodies
Anti-
mouse
Clone Dilution Supplier Cat. no
CCR2 475301 1:100 R&D Systems FAB5538A-025
CD11b M1/70 1:1000 Biolegend 101251
CD11c N418 1:500 Biolegend 117348
CD138 281-2 1:100 Biolegend 142503
CD19 1D3 1:300 BD Biosciences 564296
CD1d 1B1 1:100 eBioscence
(ThermoFisher)
46-0011-82
CD21 7G8 1:200 BD Biosciences 747763
CD23 B3B4 1:100 Biolegend 101614
CD25 PC61 1:300 Biolegend 102051
CD3 145-2C11 1:300 Biolegend 100351
CD4 GK1.5 1:300 Biolegend 100449
CD43 S7 1:100 BD Biosciences 560663
CD44 IM7 1:500 Biolegend 103032
CD45 30-F11 1:300 Biolegend 103139
CD45R
(B220)
RA3-6B2 1:300 BD Biosciences 563793
CD5 53-7-3 1:300 Biolegend 100627
CD62L MEL-14 1:500 Biolegend 104408
CD8a 53-6.7 1:300 Biolegend 100759
FoxP3 FJK-16s 1:200 eBioscence
(ThermoFisher)
17-5773-80
IgD 11-26c.2a 1:400 BD Biosciences 564274
IgM II/41 1:400 eBioscence
(ThermoFisher)
61-5790-82
IL-7R A7R34 1:200 Biolegend 135014
KLRG1 2F1 1:300 Biolegend 138416
Ly6C HK1.4 1:500 Biolegend 128024
Ly6G 1A8 1:500 Biolegend 127633
Ly6G/
Ly6C
(Gr1)
RB6-8C5 1:500 Biolegend 108441
NK1.1 PK136 1:300 Biolegend 108728
PDL1 10F.9G2 1:400 Biolegend 124319
Siglec-F E50-2440 1:500 BD Biosciences 552126
TCRβ H57-597 1:300 Biolegend 109224
γδTCR UC7-13D5 1:100 Biolegend 107504
Anti-
human
CD19 SJ25C1 1:100 BD Biosciences 563326
CD24 ML5 1:100 BD Biosciences 562789
CD38 HIT2 1:50 BD Biosciences 555459
IL-10 JES3-9D7 1:12.5 Miltenyi Biotec 130-096-043
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05674-8
14 NATURE COMMUNICATIONS |  (2018) 9:3174 | DOI: 10.1038/s41467-018-05674-8 | www.nature.com/naturecommunications
on preliminary experiments showing a median survival time of
50 h. In experiments where analysis of different cell subsets or
gene expression analysis is the main end point, groups of 6–8
mice is sufﬁcient. Regardless of the cohort size, experiments were
repeated at least once in order to determine inter-experimental
variability as well as inter individual variability. We have arrived
at these numbers in consultation with statisticians at the Babra-
ham Institute and at GSK.
Samples were excluded from analysis only when there was a
known technical problem affecting the analysis. For in vivo
studies, genetically modiﬁed mice and wild-type mice were age
and sex matched. PI3Kδ inhibitor and vaccine treatment groups
were also age and sex matched to vehicle control groups. Wild-
type littermates were from p110δE1020K colonies and were co-
housed with p110δE1020K mice. For other strains (e.g.,
p110δD910A), p110δE1020K littermates or C57bl/6 mice from the
Babraham Institute breeding colony were used as controls. Gene
array samples were randomized by GSK statisticians prior to
shipping for mRNA extraction by Expression Analysis, Quintiles.
Blinding. In vivo studies were blinded as follows: animals were
genotyped and allocated to age and sex matched treatment
groups. Pneumovax immunization was performed by technicians
not involved in study design, analysis or interpretation. The
genotype and vaccine treatment information was hidden on the
experimental study sheets and mouse cages. Mice were identiﬁed
by implanted microchips, so the identity was not apparent to
operator. Intranasal infections and monitoring were done without
knowledge of genotypes. Genotype and vaccine treatment group
information was only revealed at the study endpoint. Monitoring
in PI3Kδ inhibitor treatment studies was not fully blinded due to
practical constraints: the researcher performing the intranasal
treatment also prepared the compound formulation. However,
genotypes were blinded in these studies as described above, and
intranasal infections were performed without knowledge of gen-
otype or PI3Kδ inhibitor treatment group. For all studies, mon-
itoring was shared between 1−2 researchers and 3 technicians not
responsible for the design, analysis or interpretation of the study.
In vitro studies were not blinded.
Data analysis. Data analysis was performed in Graphpad Prism.
We performed a D’Agostino & Pearson normality test for sample
sizes of n > 8, and a Shapiro–Wilk normality test for sample sizes
of n < 8. For data sets following a Gaussian distribution, we used
student’s t-test with Welch’s correction to account for samples
with unequal variance where two groups were compared and one-
way ANOVA with Tukey’s multiple comparisons test where three
or more groups were compared. For data sets that did not follow
a Gaussian distribution we performed the following non-
parametric tests: where two groups were compared we used the
Mann–Whitney test. Where three or more groups were com-
pared, we used the Kruskal–Wallis test with Dunn’s multiple
comparison test. All tests were two-sided without matching or
pairing of values to be compared. Survival data was analyzed
using the Gehan-Breslow-Wilcoxon test. p-values are indicated in
individual ﬁgures, and in all cases we considered results statisti-
cally signiﬁcant when p ≤ 0.05.
Data availability. Gene array data have been deposited in the
National Center for Biotechnology Information Gene Expression
Omnibus (GEO) and are accessible through GEO series accession
number GSE109941. All data is available from the authors on
request.
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